Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
Date:8/5/2009
Page Overview of Financial Results 6 Financial Information 13 Notes to Editors 26 Safe Harbor Statement 26 Explanation of Non GAAP Measures 26 Trademarks 27
Dial in details for the live conference call for investors 14:00 BST/09:00 EDT on August 5, 2009:
UK dial in: 0808-100-5150 or 01296-311-652
US dial in: 1-8662977327 or 1-7183541176
International dial in: +44(0)1296-311-652
Password/Conf ID: 515 749#
Live Webcast:http://www.shire.com/shire/InvestorRelations/index.jsp?tn=2
OVERVIEW OF FINANCIAL RESULTS
1. Introduction
Summary of Q2 2009
Revenues from continuing operations for the three months to June 30, 2009 decreased by 19% to $629.7 million (2008: $775.6 million), primarily due to the decline in branded ADDERALL XR product sales in Q2 2009 following the launch of an authorized generic version by Teva in April 2009. Excluding ADDERALL XR, product sales increased by 20% to $491.0 million (2008: $409.3 million).
Non GAAP operating income for the three months to June 30, 2009 decreased by 53% to $115.5 million (2008: $246.5 million). The lower product sales of ADDERALL XR in Q2 2009 were partially offset by higher revenues from other products and lower operating expenses, as the Company benefits from its more diversified portfolio and continues to focus on cost management, with some additional benefits from foreign exchange compared to 2008.
US GAAP operating income from continuing operations for the three months
to June 30, 2009 increased by $102.0 million to $34.7 million (2008: $67.3
million loss). US GAAP operating in
'/>"/>
| SOURCE Shire Plc Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
2. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
3. Shire begins the year with a strong performance
4. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
5. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
6. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
7. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
8. Publication of Shire plcs Annual Report 2008
9. Shires Project Playground Gives Boost to Philadelphia
10. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
11. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
Post Your Comments:
(Date:5/19/2013)... 2013 The JM Internet Group (web: ... has proudly announced that the company's YouTube channel on ... 175,000 views on YouTube. The company uses YouTube as ... tips and training for small businesses with much success. ... YouTube tips helpful for their SEO strategies", explained Jason ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Dr. Sparano ... and Women’s Health at the Albert Einstein College of ... at the Montefiore Medical Center. He is also ... Center and leads the Einstein Breast Cancer Working Group, ... translational breast cancer research. He also serves as Vice ...
(Date:5/17/2013)... transplant recipient,s immune system identifies the transplanted organ as ... that T cells, the immune cells that mediate rejection, ... in order to migrate to the transplanted organ. In ... , Fadi Lakkis and colleagues at the University of ... T cells is not required for migration. Instead, these ...
(Date:5/17/2013)... 17, 2013 - Elsevier, a world-leading provider of scientific, ... the publication of a recent study in ... blastocysts showing that those with an abnormal chromosomal composition ... have developed to blastocysts, thereby classifying the risk of ... the same group has undertaken a retrospective study, using ...
Breaking Biology Technology:YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3... and the public agree that the promise of nanotechnology is ... be governed accordingly. , The new technology, which is ... to computers, is seen differently among scientists than the general ... areas. But in broad categories of risk versus reward both ...
... N.Y., Feb. 15 EUSA Pharma (Oxford, UK), ... licensed OP-R003,a human anti-interleukin-6 antibody discovered by Vaccinex, ... product license, GSK will pay an up-front,license fee, ... the exclusive world-wide rights to develop and commercialize,OP-R003 ...
... Data presented at the 2008 Genitourinary Cancers ... OncoGenex Technologies Inc. announced,today that the Company,s ... as custirsen, was well-tolerated in combination with ... in patients with,hormone refractory prostate cancer. Additionally, ...
Cached Biology Technology:Nanotech's health, environmental impacts worry scientists and the public 2Nanotech's health, environmental impacts worry scientists and the public 3Vaccinex Antibody Licensed to GlaxoSmithKline 2OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 2OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 3OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer 4(Date:5/19/2013)... reports that white men and women of European descent ... and lesser toe deformities, including hammer or claw toe. ... the heritability of foot disorders in humansappear in ... Wiley on behalf of the American College of Rheumatology ... as 60% of older adults have foot disorders which ...
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) explores ... and lifestyle. , Individuals suffering from Crohn,s ... fatigue and poor quality of life. These symptoms ... A randomized, double blind, placebo-controlled study found for ... to significant relief of these symptoms. , ...
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
Breaking Biology News(10 mins):Blame your parents for bunion woes 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3First Atlanta Science Festival set for 2014 2... may emerge from a laboratory model that has just been ... human immune stem cells from umbilical cord blood into mice ... live alongside the mouse,s own immune system. Although mice ... causes typhoid fever, the bacteria are able to reproduce in ...
... Md. (September 22, 2010) The National Science Foundation ... Science Chesapeake Biological Laboratory $1.7 million to repair and ... Since 1936, the pier has played an instrumental role ... on climate change, fisheries management and the health of ...
... The antibacterial ingredient in some soaps, toothpastes, odor-fighting socks, ... long-sought new treatment for a parasitic disease that affects ... became the guiding light for future development of drugs ... Medicinal Chemistry . In the study, Rima McLeod ...
Cached Biology News:Humanized mice may provide clues to better prevent and treat typhoid fever 2Humanized mice may provide clues to better prevent and treat typhoid fever 3UMCES Chesapeake Biological Laboratory to rebuild historic research pier 2Complete cell culture media with cytokines...
Request Info...
Contains 0.2 g/L EDTA4Na in phosphate-buffered saline....
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C ... Cl N O 6 ,M.W.= ... ,Solution: Clear (2% in DMF) ,Biological ... and M13 ,Elemental Analysis: Agrees with ...
Biology Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |